Health Technology Assessment Health Technology Assessment
is the systematic evaluation of properties, effects, and/or impacts of health technology is the systematic evaluation of properties, effects, and/or impacts of health technology


CDE (the Center for Drug Evaluation)

The Center for Drug Evaluation (CDE) was established by the Department of Health (DOH) of Taiwan on July 13, 1998 as a non-government, non-profit organization. The main task of CDE was to evaluate new drugs and new medical devices for regulatory requirements commissioned by DOH. Founded by sponsorship of the DOH in 2008, CDE started to build a transparent and scientific HTA system in Taiwan, the Division of HTA (CDE/HTA), with the mindset of conducting evidenced-based assessments. One of the major tasks of CDE/HTA is to provide assistance to Bureau of National Health Insurance (BNHI) on the decision making of new drug listing. BNHI is the reimbursement body which now covers 99% of population and contracts with 91.5% of healthcare providers in Taiwan. Among more than 150 full time staffs in CDE, there are thirteen persons working in HTA division now with various backgrounds including physician, pharmacy, nursing, epidemiology, statistics, health economics, health informatics, and so on. With the vision "Regulatory Science, Service for Life", CDE plays a pivotal role in enhancing the efficiency and quality of drug and device evaluation, thus promoting public health and welfare including timely access to innovative medicines. CDE/HTA’s mission is to provide evidenced-based assessments to decision makers and support for decision-making processes.

CNHDRC (China National Health Development Research Center)

China National Health Development Research Center (formerly known as the China Health Economics Institute), a research institution established in 1991 under the leadership of the Chinese Ministry of Health (MoH), is a national think tank providing technical consultancy to health policy makers in the country. After decades of development, China Health Economics Institute (CHEI) has become an institution of scale, with 82 registered researchers, 25 contract-based or temporarily-deployed research fellows, 8 internationally-famous scholars as chief experts or invited research fellows. Among the employees, there are 16 with PHD titles, 63 with master degrees, 42 Party members, 22 with advanced professional titles, and 32 with secondary professional titles. To further strengthen health policy research and better accommodate the needs of health development and reform, CHEI formally changed its name to the China National Health Development Research Center (CNHDRC) on March 12, 2010 after being approved by the Chinese Staffing Committee. Its missions are 1) to conduct research on health development and reform strategy and take part in health development and reform programs; 2) to conduct research on public health policy and provide health policy-makers with policy recommendations; 3) to conduct health management research and implement relevant programs; 4) to conduct research and programs on health policy and health technology evaluation; 5) to conduct research on health economics and health management theories and methodologies and implement relevant programs.

DSAP (Discipline of Social & Administrative Pharmacy)

Discipline of Social & Administrative Pharmacy (DSAP) was established in 2005 as an academic unit in Universiti Sains Malaysia (the only one to date) to develop the nation capacity to appraise/use health technology and service rationally. This is in line with the university APEX aspiration to achieve and advocate sustainability for the country and society. Apart from HTA, the unit also works as research and referral centre to explore the complex interactions among government and non-governmental agencies, providers, consumers and policy-makers in health system. The mission of the DSAP is to educate future and present health care professionals to become competent and innovative researchers, educators and administrators with a critical understanding of health care services, health economics and administrative sciences. Specifically, the discipline seeks to serve as a catalyst to: 1) Enhance the quality of professional and graduate education within the school and university; 2) Generate and communicate knowledge through innovative research to improve pharmacy services, healthcare outcomes, health & pharmaceutical policy and pharmacy education; and 3) Contribute to community well being through service in the domain of the social, administrative and educational pharmaceutical sciences. It now has four faculty staff members (one expert in health economic, one expert in pharmacy practice, one expert in clinical pharmacy, and one pharmaceutical marketing expert) and four support staff.

EMTD (Essential Medicines and Technology Division, Department of Medical Services Bhutan)

Essential Medicines and Technology Division (EMTD) is a division under the Department of Medical Services, Ministry of Health Bhutan. It was established under the approval from the cabinet in the year 2008. It looks after the essential drugs and technologies that exists and are to be introduced in the country. The aims of EMTD are (1) to provide different sectors the support they require for adopting best practices for the sustainable and safe use of medicinal products and health technology and promoting access to health services; (2) to introduce evidence-based medicines, treatment interventions and technologies that provide cost effective solutions to health problems through regular reviews and studies; (3) to revise and publish Essential Drugs List, Bhutan National Formulary, Standard Treatment Guideline & National Antibiotics Guideline, HTA Guideline; (4) to plan and conduct activities to upgrade knowledge on all matters related to pharmaceuticals and health technologies; (5) to coordinate the monitoring and supervision of utilization of medical supplies at all levels at regular intervals; (6) to study the impact, implication, development and use of health technology and to introduce policies based on social, ethical, economic and medical studies; and (7) to develop National Service Standards at different level of health facilities.

HITAP (The Health Intervention and Technology Assessment Program)

HITAP was established in 2007 as a non-profit organization which itself reports to the Bureau of Policy and Strategy, Office of the Permanent Secretary of the Ministry of Public Health, Thailand. HITAP’s main responsibility is to assess a range of health interventions and technologies, including pharmaceuticals, medical devices, clinical practices, individual and community health promotions and disease prevention programs, as well as social health policy. HITAP aims to cultivate the public interest and motivate participation from all sectors in society in order to efficiently distribute and allocate the limited resources to fulfill its public objectives. Its missions are 1) To efficiently and transparently appraise health interventions and technologies by using international, standard and qualified research methodologies; 2) To develop systems and mechanisms in order to promote the optimal selection, procurement and management of health technology as well as appropriate health policy determination; 3) To distribute research findings and educate the public in order to make the best use of health interventions and technology assessment results.

HSPI (Health Strategy and Policy Institute, Vietnam)

Health Strategy and Policy Institute (HSPI) is a research institution which has official functions of: (1) conducting research to provide evidence to Ministry of Health and related stakeholders for policy making in Vietnam; (2) providing consultations and playing a crucial role, as an advocate as well as critic, on the issues of health policies and strategies to Ministry of Health; (3) Training in the areas of health policy and health system; and (4) International cooperation in health strategy and policy research and development. Since its establishment in 1998, HSPI has made important contribution to policy development in Vietnam. The Institute directly involved in developing a number of recent health policies including: Health Insurance Law (2008,2014), National policies on Alcohol Control (on-going), National Strategy for Healthcare for People and protection 2011-2020 and vision to 2030 (2013). The Health Strategy and Policy Institute has had many years of experience in coordinating and managing bilateral or multilateral cooperation projects on health and health system.

IHPP (International Health Policy Program, Thailand)

The Thai International Health Policy Program (IHPP) started through the Senior Research Scholar program in 1998 and was officially established in 2001 under a Memorandum of Understanding (MOU) between the Ministry of Public Health (MOPH) and the Health System Research Institute (HSRI). IHPP is a semi-autonomous program that conducts research on national priorities related to health systems and policy in Thailand and overseas. IHPP also has played a critical role in strengthening national capacity for health policy and systems research (HPSR), and has also become a valuable regional and international resource for technical support and leadership particularly on health financing issues. The Program is currently located under the MOPH Bureau of Policy and Strategy. IHPP's vision is to be a leading institute in HPSR for evidence-based policy making. IHPP objectives are (1) to strengthen individual and institutional capacity in health policy and system research; (2) to conduct health policy and system research to address priority health problems at the national, regional and global levels; and (3) to communicate research findings to support evidence-based policy decisions.

MaHTAS (Health Technology Assessment Section, Ministry of Health Malaysia)

The Malaysian Health Technology Assessment (MaHTAS) was established in August 1995, under the Medical Programme, Ministry of Health Malaysia, in keeping with the Ministry´s policy of ensuring that safe, effective and cost effective technology is being used in the Ministry of Health facilities in Malaysia. Initially, reports on health technology assessment were the only output of this section. The scope of activities of this section was expanded in 2001 to include development of national evidence-based Clinical Practice Guidelines and rapid assessment of technologies which are named as Technology Reviews. In 2009, activities on implementation of CPG were introduced. Our vision is to ensure appropriate use of health technologies by influencing decision-makers through collection, analysis, and dissemination of information on safety, effectiveness, cost-effectiveness and health impact of technologies. Our mission is to provide evidence for informed decision making to policymakers, health care providers and consumers.

MOH (Ministry of Health, Singapore)

The Ministry of Health (MOH) in Singapore has the mission to promote good health and reduce illness, ensure access to good and affordable healthcare, and pursue medical excellence. Since September 1995, the Ministry has had a formal unit with health technology assessment (HTA) functions. In 1997, the MOH clinical practice guidelines programme was established and administered by the HTA unit. Today, the HTA Branch is part of the Performance and Technology Assessment Division and it carries out HTA to inform decisions and policy-making within the MOH and develops clinical practice guidelines to recommend evidence-based clinical practices to medical practitioners in Singapore.

NCPAM (National Center for Pharmaceutical Access and Management, Department of Health Philippines)

The National Center for Pharmaceutical Access and Management (NCPAM) is the Office within the Philippine Department of Health tasked to improve access to essential medicines. Established from an ad-hoc unit in January 2010, the DOH-NCPAM was created to operationalize, strategize and implement provisions of the Philippine Republic Act 9502 or the Universally Accessible and Affordable Quality Medicines Act of 2008. Specifically, the overall goals of the DOH-NCPAM are (1) to improve the supply side access to quality essential medicines; (2) to ensure rational use of medicines by prescribers, dispensers and patients, and (3) to institutionalize transparency and good governance in the pricing and procurement of medicines. A core function of the DOH-NCPAM is the governance and management of the Philippine National Formulary, which is the list of essential medicines approved for government procurement and national health insurance reimbursement. To ensure the cost-effectiveness of drugs included in the national formulary, it is important that formal methods on pharmacoeconomic evaluation and health technology assessment are institutionalized in the process of decision-making. The DOH-NCPAM undertakes drug reviews for the Formulary Executive Council (FEC) jointly with academic partners and researchers ensuring that the rigorous review process and decision-making are done with principles of scientific integrity, transparency, accountability and good governance.

NECA (National Evidence-Based Healthcare Collaborating Agency)

NECA was established on December 2008 to contribute to the efficiency of health spending and the activation of the healthcare industry by providing objective and scientific evidence to consumers, insurers, and healthcare providers based on the economic evaluation and clinical efficacy of health technologies and products. Our strategic goals are drafting social agendas and presenting policies in the area of healthcare, drafting optimum medical technologies, assessment of new medical technologies for rational introduction, comparative assessment of medical technologies for efficient utilization of medical resources, globalization of medical technology assessment, supporting policy-makers on national evidence-based healthcare services, and dissemination of research outcomes meeting various demands. In 2010, NECA was apsiteed as the lead research agency for the National Strategic Coordinating Center for Clinical Research (NSCR) and took over the Center for New Health Technology Assessment (CNHTA) from the Health Insurance Review and Assessment Service (HIRA). Since its establishment, NECA has been assessed various healthcare services/technologies and released the results of these assessments, which made a great impact on the public. In addition, NECA has been putting an effort to collaborate with international agencies and governmental organizations related to Health Technology Assessment (HTA).

PSD (Pharmaceutical Services Division, Ministry of Health Malaysia)

Pharmacy Services is one of the programs under the Ministry of Health Malaysia (MOH), which is responsible for ensuring all pharmaceutical products and health products in the market are of quality, safe, efficacious, regulated according to the relevant legislations, and used rationally. Pharmacy Services at MOH headquarters which is the Pharmaceutical Services Division carries out this responsibility through three main activities namely Policy & Management, Pharmacy Practice & Development, and Enforcement. Our vision is to lead in quality management of medicines through a competent workforce and appropriate science and technology development; in partnership with stakeholders and the mission is to ensure quality medicines for the nation.

ASERNIP-S (the Australian Safety and Efficacy Register of New Interventional Procedures – Surgical, Australia)

The mission of the Australian Safety and Efficacy Register of New Interventional Procedures - Surgical (ASERNIP-S) is to provide quality and timely assessments of surgical technologies and techniques. Services provided include: (1) full and rapid systematic reviews, and technology overviews of the peer-reviewed literature; (2) the establishment and facilitation of clinical and research audits or studies; (3) the assessment of new and emerging techniques and technologies by horizon scanning; (4) input into the production of clinical practice guidelines. The ultimate aim is to improve the quality of healthcare through the wide dissemination of our evidence-based research to surgeons, healthcare providers and consumers, both nationally and internationally.


HealthPACT was established in late 2003 as part of a Commonwealth initiative to provide "early warning" to Australian and New Zealand policy makers of the consequences (positive or negative) of new and emerging devices, diagnostics, programs and surgical techniques, with pharmaceuticals, vaccines and blood products not being part of HealthPACT's remit. The HealthPACT committee comprises of representatives from the Australian Government and each of its states and territories, the Commonwealth Medical Services Advisory Committee, the Therapeutic Goods Administration, the Department of Veteran Affairs and the New Zealand Health Ministry. Although several changes to the governance of HealthPACT have occurred over the years, the remit of the Committee has remained constant in that it aims to enable clinicians and health departments to future proof the health service by making informed decisions on the adoption and diffusion of new technologies based on evidence. During the nine years since its inception, HealthPACT has overseen the assessment of 380 new and emerging health technologies and has provided further updates on 139 of these assessments. Since its establishment, HealthPACT has increased interaction with jurisdictional, state-based HTA assessment committees (QPACT, WAPACT and VPACT) to avoid duplication of effort and has sponsored several workshops of national interest to facilitate an exchange of information. In addition, HealthPACT is working to develop stronger links with industry to identify issues such as infrastructure and training required, especially for complex and expensive technologies.

NICE (the National Institute for Health and Clinical Excellence)

The National Institute for Health and Clinical Excellence (NICE), is part of the British National Health Service (NHS). Since its establishment in 1999, NICE has been advising the NHS on the use of medical technologies and on best clinical practice. More recently, NICE has become responsible for developing Quality Standards, that is, evidence-informed statement of best practice, which will drive reimbursement as well as regulation and performance management, across the NHS, including the primary care Quality and Outcomes Framework. Furthermore, NICE runs NHS Evidence, an electronic portal offering access to accredited sources of information for professionals, patients and researchers. Since 2008, NICE International has been operating within NICE, working closely with overseas governments and governmental organisations, interested in using clinical and economic evidence to inform resource allocation decisions, through transparent and consultative processes.